- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02773251
The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Methods This was a prospective, randomized, controlled, single-blind, parallel-group study using HA/CMC (marketed as Guardix-sol®, Hanmi Medicare, Seoul, Korea) in patients who underwent laparoscopic radical prostatectomy between November 2011 and June 2014. All the patients were informed in detail about the aims and the procedures of the study and they signed a written informed consent prior inclusion into the study. The protocol and the written informed consent were approved by the local ethical committee (Catholic Medical Center, Clinical Research Coordinator Center; approval number XC11DIMI10098H).
Subjects Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic radical prostatectomy. Exclusion criteria included any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
Study design and protocol The laparoscopic radical prostatectomy was performed in same surgical procedures and steps by two surgeons (USH and JSK) who have experienced over 150 cases of laparoscopic radical prostatectomy. The laparoscopic radical prostatectomy was performed using the five-port fan-shaped transperitoneal approach. After the introducing the peritoneal cavity, incising the parietal peritoneum between the medial umbilical ligaments are incised and dissection is carried through the fatty alveolar tissue to develop the space of Retzius. After that, the surgical steps are following order (1) incision of the endopelvic fascia; (2) ligation of the dorsal vein complex; (3) division of the bladder neck; (4) dissection of the seminal vesicles; (5) incision of the Denonvillier fascia and control of the lateral pedicles with antegrade neurovascular bundle dissection; (8) apical dissection and division of the dorsal vein and the urethra; (9) urethrovesical anastomosis.
Considering about 30% of dropout rate (under the assumption of 40% difference between HA/CMC treatment group and the control group based on previous similar study, by which the target enrollment for this trial was 60 subjects (30 subjects per group). The sample size was determined assuming a level of significance of α=0.05 (two-side) and a 80% statistical power of test. All patients were randomly assigned to either the HA/CMC treatment group (n=30) or the control group (n=30) using a computer-generated randomization table. The surgeon was blinded to treatment assignments before randomization. Patients were also blinded to their treatment group throughout the study. HA/CMC was applied in all port sites and the peritoneal incision line of the medial umbilical ligament with a single-use applicator attached to a sprayer that allowed for the precise application to the required sites. The amount of HA/CMC applied was 5 ml. Information regarding the duration of illness and medical history were collected at the time of enrollment (V0). Viscera slide ultrasound and plain X-ray were recorded at the time of the operation (V0) and 12 (V1) and 24 week (V2) after the operation.
The primary end point was the difference in excursion distance on viscera slide ultrasound between V0 and V2. The secondary end point was excursion distance on viscera slide ultrasound at V2 and the presence of restriction of viscera slide on ultrasound at V2.
Assessment of efficacy and safety Twelve and 24 weeks after the operation, bowel adhesion to the abdominal wall was evaluated by ultrasound and plain X-rays. We performed viscera slide ultrasound according to a technique that has been previously described. By dividing the abdomen into 5 segments and examining the viscera slide in each segment, a prediction of the extent of the adhesions was made for each patient. At the time of the viscera slide ultrasound, data were also collected on the location of the scars on the abdomen. The main point of interest was the distance of the longitudinal excursion of the selected area in relation to the fixed abdominal wall. Normal viscera sliding movement was defined as equal to or greater than 1 cm of longitudinal movement. Restricted viscera slide was defined as less than 1 cm of longitudinal movement during both normal and exaggerated respiration. The ultrasound was performed by two sonographers who had been well instructed for study assessment. The assessment by ultrasound was double-checked. The sonographer, radiologist and all accessor was blind to the randomization during the all study period.
Statistical Analysis The data for this study are expressed as mean ± standard deviation of the mean. The comparisons of the 2 groups were made using a chi-test, an independent Student's t test, or repeated measure ANOVA. P-values <0.05 were considered significant. Statistical calculations were carried out with IBM SPSS statistics, Version 21 (IBM Corp, Armonk, NY).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic pelvic surgery (radical prostatectomy).
Exclusion Criteria:
- any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: hyaluronic acid-carboxymethylcellulose treatment group
the HA/CMC treatment group after laparoscopic pelvic surgery
|
|
|
NO_INTERVENTION: control group
the HA/CMC non-treatment group after laparoscopic pelvic surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the difference in excursion distance on viscera slide ultrasound between V0 and V2.
Time Frame: within the first 6 months after surgery
|
within the first 6 months after surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XC11DIMI10098H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.Active, not recruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer... and other conditionsUnited States
Clinical Trials on hyaluronic acid-carboxymethylcellulose
-
Winthrop University HospitalStony Brook University; Lehigh Valley HospitalCompletedCesarean Section | Adhesions | Delivery, ObstetricUnited States
-
Istanbul Medipol University HospitalCompleted
-
Kafrelsheikh UniversityNot yet recruitingDental Implant FailedEgypt
-
Hallym University Dongtan Sacred Heart HospitalMinistry of Science and ICT, Republic of KoreaActive, not recruitingRotator Cuff TearSouth Korea
-
AllerganCompleted
-
Ordu UniversityCompletedGingival RecessionTurkey (Türkiye)
-
Ayhman Al AfifNova Scotia Health AuthorityCompletedHead and Neck Neoplasms | Laryngeal Cancer | Head and Neck Squamous Cell Carcinoma | Voice Disorders
-
Cellcolabs Clinical SPV LimitedRecruiting
-
King Abdulaziz UniversityActive, not recruitingPapilla ReconstructionSaudi Arabia